4-(3-fluoropropoxy)-3-methoxybenzaldehyde | 914394-70-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-fluoropropoxy)-3-methoxybenzaldehyde
• CAS: 914394-70-0
• 化学式: C₁₁H₁₃FO₃
• 分子量: 212.221
• InChiKey: PMZFVCKKOQXZKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-fluoropropoxy)-3-methoxybenzaldehyde 在 sodium tetrahydroborate 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 为溶剂， 生成 2-(tert-butyl)-4-chloro-5-((4-(3-fluoropropoxy)-3-methoxybenzyl)oxy)pyridazin-3(2H)-one
  参考文献：
  名称：

  COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS

  摘要：

  本发明提供了具有成像基团的化合物，用于对受试者进行成像。本发明还涉及用于合成和使用成像试剂或其前体的系统、组合物和方法。成像试剂前体可以使用本文所述的方法转化为成像试剂。在某些情况下，组合物或多种成像试剂富集于 18 F。在某些情况下，成像试剂可用于成像受试者的感兴趣区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。

  公开号：

  US20150196672A1
• 作为产物：
  描述：

  4-(3-bromopropoxy)-3-methoxybenzaldehyde 在 四丁基氟化铵 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 4.0h， 生成 4-(3-fluoropropoxy)-3-methoxybenzaldehyde
  参考文献：
  名称：

  Curcumin and Dehydrozingerone Derivatives:  Synthesis, Radiolabeling, and Evaluation for β-Amyloid Plaque Imaging^†

  摘要：

  Alzheimer's disease (AD) is pathologically characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain, and thus, the in vivo imaging of plaques and tangles would be beneficial for the early diagnosis of AD. It has been suggested that 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)1,4,6-heptatrien-3-one (curcumin) may be responsible for low age-adjusted prevalence of AD in India. In the present study, eight novel derivatives of curcumin and 4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one (dehydrozingerone) were synthesized and their binding affinities for beta-amyloid (A beta) aggregates were measured. Of these ligands, fluoropropyl-substituted curcumin (8) showed the highest binding affinity (K-i = 0.07 nM), and therefore, 8 was radiolabeled and evaluated as a potential probe for A beta plaque imaging. Partition coefficient measurement and biodistribution in normal mice demonstrated that [F-18]8 has a suitable lipophilicity and reasonable initial brain uptake. Metabolism studies also indicated that [F-18]8 is metabolically stable in the brain. These results suggest that [F-18]8 is a suitable radioligand for A beta plaque imaging.

  DOI：

  10.1021/jm0607193

文献信息

• Synthesis and characterization of ¹⁸F-labeled hydrazinocurcumin derivatives for tumor imaging
  作者：Sarah Shin、Hyun-Jung Koo、Iljung Lee、Yearn Seong Choe、Joon Young Choi、Kyung-Han Lee、Byung-Tae Kim

  DOI：10.1039/c5ra15380h

  日期：——

  Radiolabeled hydrazinocurcumin derivatives, [¹⁸F]1 and [¹⁸F]2 were synthesized and both radioligands were resistant to reductive metabolism. MicroPET images of C6 glioma xenografted mice showed high tumor uptake and retention of [¹⁸F]2.

  放射标记的肼基姜黄素衍生物，[¹⁸F]1 和 [¹⁸F]2 已合成，两种放射配体都对还原代谢具有抵抗性。C6胶质瘤移植小鼠的MicroPET图像显示 [¹⁸F]2 的肿瘤摄取和滞留高。
• APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F])
  申请人：Lantheus Medical Imaging, Inc.

  公开号：EP3653621A1

  公开（公告）日：2020-05-20

  An apparatus for synthesizing the imaging agent of the formula comprising a cassette as shown in Figure 17 with a linear arrangement of a plurality of stopcock manifolds arranged in the order: 1) luer connections to gas inlet and [18O]H2O recovery; 2) anion exchange cartridge - column eluting solution; 3) spike connection for acetonitrile; 4) empty syringe; 5) reservoir with solution of imaging agent precursor; 6) reaction vessel; 7) outlet to HPLC; 8) syringe with solution of a stabilizing agent; 9) inlet from HPLC; 10) ethanol reservoir; 11) syringe with solution of a stabilizing agent; 12) syringe with water; 13) final product vial; 14) empty syringe; and 15) reaction vessel and exhaust; further comprising tubing, an imaging agent synthesis module, wherein the apparatus is fluidically connected to the apparatus, and wherein the solution of a stabilizing agent comprises a solution comprising ascorbic acid or a salt thereof.

  一种合成式中成像剂的装置 包括一个如图 17 所示的盒体，盒体上直线排列着多个按顺序排列的截止阀歧管： 1）气体入口和[18O]H2O 回收的鲁尔接头； 2) 阴离子交换滤芯-柱洗脱液； 3) 用于乙腈的尖头连接； 4) 空注射器 5) 装有成像剂前体溶液的容器； 6) 反应容器 7) 连接 HPLC 的出口； 8) 装有稳定剂溶液的注射器； 9) 高效液相色谱仪的入口 10）乙醇储液器 11) 装有稳定剂溶液的注射器； 12) 装有水的注射器 13) 最终产品小瓶 14) 空注射器；以及 15) 反应容器和排气管； 进一步包括管道、成像剂合成模块，其中该装置与该设备流体连接，稳定剂溶液包括由抗坏血酸或其盐组成的溶液。
• Compositions, methods, and systems for the synthesis and use of imaging agents
  申请人：Lantheus Medical Imaging, Inc.

  公开号：US10500293B2

  公开（公告）日：2019-12-10

  The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

  本发明提供了具有成像分子的化合物，用于对主体成像。本发明还涉及成像剂或其前体的合成和使用系统、组合物和方法。成像剂前体可通过本文所述方法转化为成像剂。在某些情况下，成像剂组合物或多种成像剂富含 18F。在某些情况下，成像剂可用于成像受试者感兴趣的区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。
• JP2015531760A5
  申请人：——

  公开号：JP2015531760A5

  公开（公告）日：2015-11-05
• Synthesis and evaluation of 1-(4-[18F]fluoroethyl)-7-(4′-methyl)curcumin with improved brain permeability for β-amyloid plaque imaging
  作者：Iljung Lee、Jehoon Yang、Jung Hee Lee、Yearn Seong Choe

  DOI：10.1016/j.bmcl.2011.08.003

  日期：2011.10

  Alzheimer's disease is characterized by the accumulation of beta-amyloid (A beta) plaques and neurofibrillary tangles (NFTs) in the brain. We previously developed [F-18]fluoropropylcurcumin ([F-18]FP-curcumin), which demonstrated excellent binding affinity (K-i = 0.07 nM) for A beta(1-40) aggregates and good pharmacokinetics in normal mouse brains. However, its initial brain uptake was poor (0.52% ID/g at 2 min post-injection). Therefore, in the present study, fluorine-substituted 4,4'-bissubstituted or pegylated curcumin derivatives were synthesized and evaluated. Their binding affinities for A beta(1-42) aggregates were measured and 1-(4-fluoroethyl)-7-(4'-methyl) curcumin (1) had the highest binding affinity (K-i = 2.12 nM). Fluorescence staining of Tg APP/PS-1 mouse brain sections demonstrated high and specific labeling of A beta plaques by 1 in the cortex region, which was confirmed with thioflavin-S staining of the same spots in the adjacent brain sections. Radioligand [F-18]1 was found to have an appropriate partition coefficient (logP(o/w) = 2.40), and its tissue distribution in normal mice demonstrated improved brain permeability (1.44% ID/g at 2 min post-injection) compared to that of [F-18]FP-curcumin by a factor of 2.8 and fast wash-out from mouse brains (0.45% ID/g at 30 min post-injection). These results suggest that [F-18]1 may hold promise as a PET radioligand for A beta plaque imaging. (C) 2011 Elsevier Ltd. All rights reserved.